DRI Capital, a Canadian healthcare investment firm, is in the market with a $450 million securitization of drug royalty payments, according to a presale report published by Standard & Poor’s.

S&P has assigned a preliminary ‘BBB’ rating to $180 million of class A-1 notes and $270 million of class A-2 notes. Both classes benefit from overcollateralization of 36.2% and have a final maturity of July 2023.

Subscribe Now

Access to a full range of industry content, analysis and expert commentary.

30-Day Free Trial

No credit card required. Access coverage of the securitization marketplace, including breaking news updated throughout the day.